Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1500
- Registration Number
- NCT03599245
- Locations
- 🇧🇷
Instituto de Neurologia de Curitiba, Curitiba, Paraná, Brazil
🇧🇷Hospital Sao Lucas - PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital das Clinicas - FMUSP, Sao Paulo, São Paulo, Brazil
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT03596632
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1710
- Registration Number
- NCT03593590
- Locations
- 🇦🇹
Landesklinikum Amstetten, Amstetten, Austria
🇦🇹Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹Kepler Universitätsklinikum GmbH - Neuromed Campus, Linz, Austria
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 423
- Registration Number
- NCT03589105
- Locations
- 🇫🇷
CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France
🇫🇷Fondation Hopital Saint Joseph; Neurologie, Marseille, France
🇫🇷Centre hospitalier Annecy Genevois Site St Julien; Neurologie, Metz Tessy, France
A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03586726
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
- Conditions
- Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT03584009
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Nebraska Hematology Onco, PC, Lincoln, Nebraska, United States
🇦🇺Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia
A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT03579719
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT03570658
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai City, China
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT03559647
- Locations
- 🇩🇪
Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller, Mayen, Germany
🇩🇪Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie, Minden, Germany
🇩🇪Friedrich-Ebert-Krankenhaus Klinik f. Hämatologie/ Onkologie u. Nephrologie, Neumunster, Germany
A Study to Assess the Feasibility of an E-Health System (ZEMY) Designed to Manage Symptoms in Participants With Breast Cancer Under Anti-Cancer Treatment
- Conditions
- Breast Cancer
- Interventions
- Device: ZEMY softwareDrug: Investigator's choice of anti-cancer treatment (except immunotherapy)
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT03558490
- Locations
- 🇫🇷
Centre Francois Baclesse; Oncologie, Caen, France
🇫🇷Hopital Prive Jean Mermoz; Cancerologie, Lyon, France
🇫🇷Centre Jean Perrin; Oncologie, Clermont Ferrand, France